Afatinib vs Dacomitinib PF-00299804

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: EGFR/HER1, HER2, HER4 · full Non-Small Cell Lung Cancer pipeline

Afatinib · Gilotrif

Marketed by Boehringer Ingelheim

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT00949650 · Phase 3 · completed

The study randomly assigned 345 participants to afatinib or active chemotherapy, but it was open-label rather than blinded. Its hard clinical primary endpoint, centrally assessed progression-free survival, was statistically significantly better with afatinib, but the lack of blinding limits the strength of the evidence.

Next expected readout: December 2026 · NCT04413201 (registry estimate)

Reported efficacy

Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7) (met)

Result source: NCT01121393

Dacomitinib PF-00299804

Rights held by Pfizer; US product discontinued

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT01774721 · Phase 3 · completed

The 452 participants were randomly assigned to dacomitinib or the active comparator gefitinib, but the study was open-label rather than double-blinded. The hard clinical primary endpoint, independently assessed progression-free survival, was met in favor of dacomitinib, but the lack of blinding limits the strength of the evidence.

Next expected readout: April 2027 · NCT04946968 (registry estimate)

Reported efficacy

Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11) (met)

Result source: NCT01774721

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAfatinibDacomitinib PF-00299804
PFS, median11.2 vs 6.9vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
22 other results
14.7 vs 9.2vs Gefitinibn 227NCT01774721
11 other results
OS, median28.2 vs 28.2vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
10 other results
6.8 vs 6.3+0.5 vs placebon 480NCT01000025
8 other results
ORR67.8% vs 23%vs Gemcitabine / Cisplatin40mg · n 242NCT01121393
14 other results
7.1% vs 1.3%+5.8 vs placebon 480NCT01000025
5 other results
Duration of response, median9.7 vs 4.3vs Gemcitabine / Cisplatin40mg · n 164NCT01121393
6 other results
  • 10.5 50 mg · n 69 · Phase 2 · secondary NCT00796549
  • 17.6 n 80 · Phase 2 · secondary NCT00525148
  • 9 Afa40+Ctx500 · n 126 · Phase 1 · secondary NCT01090011
  • 3.9 Afa40 Mono · n 37 · Phase 1 · secondary NCT01090011
  • 5.8 Afa40+Ctx500 · n 36 · Phase 1 · secondary NCT01090011
  • 0 Afa40+Ctx250 · n 4 · Phase 1 · secondary NCT01090011
9.2 vs 10.1vs Erlotinibn 52NCT01360554
8 other results

PFS, median

Afatinib
11.2 vs 6.9vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
22 other results
Dacomitinib PF-00299804
14.7 vs 9.2vs Gefitinibn 227NCT01774721
11 other results

OS, median

Afatinib
28.2 vs 28.2vs Pemetrexed/Cisplatin40 mg · n 230NCT00949650
10 other results
Dacomitinib PF-00299804
6.8 vs 6.3+0.5 vs placebon 480NCT01000025
8 other results

ORR

Afatinib
67.8% vs 23%vs Gemcitabine / Cisplatin40mg · n 242NCT01121393
14 other results
Dacomitinib PF-00299804
7.1% vs 1.3%+5.8 vs placebon 480NCT01000025
5 other results

Duration of response, median

Afatinib
9.7 vs 4.3vs Gemcitabine / Cisplatin40mg · n 164NCT01121393
6 other results
  • 10.5 50 mg · n 69 · Phase 2 · secondary NCT00796549
  • 17.6 n 80 · Phase 2 · secondary NCT00525148
  • 9 Afa40+Ctx500 · n 126 · Phase 1 · secondary NCT01090011
  • 3.9 Afa40 Mono · n 37 · Phase 1 · secondary NCT01090011
  • 5.8 Afa40+Ctx500 · n 36 · Phase 1 · secondary NCT01090011
  • 0 Afa40+Ctx250 · n 4 · Phase 1 · secondary NCT01090011
Dacomitinib PF-00299804
9.2 vs 10.1vs Erlotinibn 52NCT01360554
8 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety

Coverage. Afatinib: 11 of 11 rows · Dacomitinib PF-00299804: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAfatinib
Rows use multiple source trials
Dacomitinib PF-00299804
Rows use multiple source trials
Disease Control
responder rate · % of participants
No placebo or comparator arm
83.3% (n=60)40 mga,b,c,d
NCT02208843 · Phase 4 · registry result, not featured evidence
6 other source trials
58.3% (n=12)30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
50% (n=12)40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
61.1% (n=18)40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
50.7% (n=69)50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
59% (n=41)50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
24% (n=38)40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
50% (n=16)45/60 mga,b,c,d
NCT01858389 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
17.65 months*e,b,c,d
NCT00525148 · Phase 2 · converted to months from 76.5 weeks as posted
5 other source trials
10.5 months*50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 45.5 weeks as posted
0 monthsAfa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
9 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
3.9 monthsAfa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
5.8 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
11.1 monthse,b,c,d
NCT04511533 · Phase 4 · registry result, not featured evidence
5 other source trials
2.83 months45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
12.9 months
NCT00818441 · Phase 2 · registry result, not featured evidence
12.4 months
NCT00818441 · Phase 2 · registry result, not featured evidence
10.43 months*
NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 45.2 weeks as posted
2.79 months*
NCT00548093 · Phase 2 · registry result, not featured evidence · converted to months from 12.1 weeks as posted
ORR
responder rate · % of participants
No placebo or comparator arm
62% (n=129)e,b,c,d
NCT00525148 · Phase 2
11 other source trials
50% (n=60)40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
8.5% (n=1154)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
8.3% (n=12)30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
16.7% (n=12)40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
0% (n=18)40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
13% (n=69)50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
13% (n=69) @ 96wk50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
2% (n=41)50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
0% (n=38)40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
17% (n=6)
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
25% (n=4)
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
50.5% (n=101)e,b,c,d
NCT04511533 · Phase 4 · registry result, not featured evidence
1 other source trial
6.3% (n=16)45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
Overall Survival
time to event · months
No placebo or comparator arm
26.8 monthsb,c,d
NCT00525148 · Phase 2
6 other source trials
6.14 months*30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 26.6 weeks as posted
8.75 months*40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 37.9 weeks as posted
10.02 months40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
12.92 months*
NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 56 weeks as posted
18.4 months50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
11.64 months*50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 50.43 weeks as posted
29.5 monthsf,b,c,d
NCT00818441 · Phase 2 · registry result, not featured evidence
show 1 more dose
9.3 months
NCT00818441 · Phase 2 · registry result, not featured evidence
Partial
responder rate · % of participants
No placebo or comparator arm
Partial Response
58.3% (n=24)*g,b,c,d
Partial Response
NCT01074177 · Phase na · registry result, not featured evidence · converted to % from 14 participants as posted
52.8% (n=89)*f,g,b,c,d
NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 47 participants as posted
show 1 more dose
10% (n=30)*
NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 3 participants as posted
PFS
time to event · months
No placebo or comparator arm
10.2 monthsb,c,d
NCT00525148 · Phase 2
17 other source trials
10.94 months40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
3.15 months
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
15.4 months40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
9.9 months40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
3.32 months*30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 14.4 weeks as posted
2.08 months*40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination · converted to months from 9 weeks as posted
2.76 months40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
3.67 months*
NCT02369484 · Phase 2 · registry result, not featured evidence · converted to months from 15.9 weeks as posted
1.95 months*50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence · converted to months from 8.43 weeks as posted
3.66 months*50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence · converted to months from 15.86 weeks as posted
0.94 months*40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence · converted to months from 4.07 weeks as posted
5.88 months*
NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 179 days as posted
1.38 months*
NCT02364609 · Phase 1 · registry result, not featured evidence · combination · converted to months from 42 days as posted
4.2 monthsAfa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
4.6 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
2.7 monthsAfa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
2.9 monthsAfa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
2.3 months45/60 mgf,b,c,d
NCT01858389 · Phase 2 · registry result, not featured evidence
show 1 more dose
1.6 months45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
Stable Disease
event count · % of participants
No placebo or comparator arm
Stable disease
46.2% (n=13)*b,c,d
Stable disease
NCT02369484 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
30.3% (n=89)*f,b,c,d
NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 27 participants as posted
show 1 more dose
36.7% (n=30)*
NCT00818441 · Phase 2 · registry result, not featured evidence · converted to % from 11 participants as posted
Dropout rate
n/a: no completion milestone40 mgh
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
—50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—40 mg
NCT00525148 · Phase 2
—50 mg
NCT00525148 · Phase 2
100%40mg
NCT01121393 · Phase 3
n/a: no completion milestone
NCT01523587 · Phase 3
n/a: no completion milestone40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT01853826 · Phase 3 · registry result, not featured evidence
n/a: no completion milestone
NCT01953913 · Phase 3 · registry result, not featured evidence
0%40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
28%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
—Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
0%
NCT02369484 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
0%Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
0%Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
0%
NCT01074177 · Phase na · registry result, not featured evidence
n/a: no completion milestonei
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
n/a: no completion milestone
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
79.2%
NCT04511533 · Phase 4 · registry result, not featured evidence
n/a: no completion milestone
NCT02382796 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
50%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
36.4%45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
0%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
43.3%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
48%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneDacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
n/a: no completion milestoneDacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone
NCT00769067 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
n/a: no completion milestonePF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
12.2%40 mgh
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
—50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
13.1%50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
—40 mg
NCT00525148 · Phase 2
—50 mg
NCT00525148 · Phase 2
9.9%40mg
NCT01121393 · Phase 3
17.1%
NCT01523587 · Phase 3
20%40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
12.9%
NCT01853826 · Phase 3 · registry result, not featured evidence
3.7%
NCT01953913 · Phase 3 · registry result, not featured evidence
—40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
19.3%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
—Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
22.2%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
22.7%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
41.7%40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
33.3%30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
—40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
—
NCT02369484 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
25.8%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
5%50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
—50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
17%40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
—Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
—Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
—
NCT01074177 · Phase na · registry result, not featured evidence
—i
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
—
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
—
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—
NCT04511533 · Phase 4 · registry result, not featured evidence
—
NCT02382796 · Phase 2 · registry result, not featured evidence
18.8%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
4%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
—45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
0%Dacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
3.3%Dacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
—
NCT00769067 · Phase 2 · registry result, not featured evidence
—PF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
—PF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Serious AEs
31.4%40 mgh
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 32 more results
34.9%50 mg/Day
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
—50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
30%40 mg
NCT00525148 · Phase 2
44.4%50 mg
NCT00525148 · Phase 2
16.7%40mg
NCT01121393 · Phase 3
44.4%
NCT01523587 · Phase 3
35%40 mg
NCT02208843 · Phase 4 · registry result, not featured evidence
43.8%
NCT01853826 · Phase 3 · registry result, not featured evidence
30.3%
NCT01953913 · Phase 3 · registry result, not featured evidence
21.4%40 mg
NCT02044380 · Phase 3 · registry result, not featured evidence
40.8%Afatinib Monotherapy (Part A)
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
40.3%Afatinib Plus Paclitaxel (Part B)
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
55.6%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
22.7%40 mg
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
33.3%40 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
75%30 mg + 200 mg
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
33.3%40 mg
NCT02597946 · Phase 2 · registry result, not featured evidence
38.5%
NCT02369484 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
25.8%50 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
33.3%20 mg
NCT00711594 · Phase 2 · registry result, not featured evidence
50.7%50 mg
NCT00796549 · Phase 2 · registry result, not featured evidence
46.3%50 mg
NCT00730925 · Phase 2 · registry result, not featured evidence
40.5%40 mg
NCT01003899 · Phase 2 · registry result, not featured evidence
0%Arm I (Afatinib Dimaleate, Pembrol
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
40%Arm II (Pembrolizumab, Afatinib Di
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
75%Afa40+Ctx250
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
50%Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
32.4%Afa40 Mono
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
41.7%Afa40+Ctx500
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT01074177 · Phase na · registry result, not featured evidence
30.4%i
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
40.8%
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
40%
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
15.8%
NCT04511533 · Phase 4 · registry result, not featured evidence
28.6%
NCT02382796 · Phase 2 · registry result, not featured evidence
43.8%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
36.4%45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
37.9%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
40.9%45 mg + 100 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
42.9%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
32.8%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
24%45 mg
NCT01465802 · Phase 2 · registry result, not featured evidence
32.6%Dacomitinib: Cohort A
NCT00818441 · Phase 2 · registry result, not featured evidence
30%Dacomitinib: Cohort B
NCT00818441 · Phase 2 · registry result, not featured evidence
36.6%
NCT00769067 · Phase 2 · registry result, not featured evidence
18%PF-00299804 (Adenocarcinoma Histol
NCT00548093 · Phase 2 · registry result, not featured evidence
37.5%PF-00299804 (Non-adenocarcinoma Hi
NCT00548093 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
40 mgh
diarrhoea 94.3%
rash 63.3%
paronychia 57.6%
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 31 more results
50 mg/Day
diarrhoea 85.6% (placebo 9.2%)
rash 63.6% (placebo 11.8%)
paronychia 33.6% (placebo 0.5%)
NCT00656136 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
40 mg
diarrhoea 96.7%
paronychia 66.7%
rash 66.7%
NCT00525148 · Phase 2
50 mg
diarrhoea 92.9%
paronychia 79.8%
rash 75.8%
NCT00525148 · Phase 2
40mg
diarrhoea 88.7%
rash 73.2%
paronychia 33.5%
NCT01121393 · Phase 3
diarrhoea 72.4%
rash 50%
decreased appetite 24%
NCT01523587 · Phase 3
40 mg
diarrhoea 73.3%
rash 30%
paronychia 23.3%
NCT02208843 · Phase 4 · registry result, not featured evidence
diarrhoea 49.7%
rash 29.9%
paronychia 17.7%
NCT01853826 · Phase 3 · registry result, not featured evidence
diarrhoea 89.3%
rash 70.8%
paronychia 50.1%
NCT01953913 · Phase 3 · registry result, not featured evidence
40 mg
diarrhoea 92.9%
decreased appetite 42.9%
nausea 42.9%
NCT02044380 · Phase 3 · registry result, not featured evidence
diarrhoea 83.5%
rash 54.5%
paronychia 29.6%
NCT01085136 · Phase 3 · registry result, not featured evidence · monotherapy
diarrhoea 53.7%
alopecia 35.1%
asthenia 35.1%
NCT01085136 · Phase 3 · registry result, not featured evidence · combination
40 mg
diarrhoea 88.9%
nausea 66.7%
dry skin 44.4%
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
40 mg
diarrhoea 81.8%
constipation 50%
dermatitis acneiform 36.4%
NCT01814553 · Phase 3 · registry result, not featured evidence · combination
40 mg + 200 mg
diarrhoea 91.7%
decreased appetite 50%
rash 41.7%
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
30 mg + 200 mg
diarrhoea 58.3%
dermatitis acneiform 41.7%
fatigue 33.3%
NCT03157089 · Phase 2 · registry result, not featured evidence · combination
40 mg
diarrhoea 66.7%
rash 33.3%
anaemia 22.2%
NCT02597946 · Phase 2 · registry result, not featured evidence
diarrhea 84.6%
paronyclia 38.5%
erythema multiforme 30.8%
NCT02369484 · Phase 2 · registry result, not featured evidence
40 mg
nausea 100%
rash 100%
stomatitis 100%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 100%
dry skin 83.3%
acne 50%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 93.5%
rash 85.5%
paronychia 67.7%
NCT00711594 · Phase 2 · registry result, not featured evidence
20 mg
dry skin 100%
malaise 100%
rash 100%
NCT00711594 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 76.8%
rash 73.9%
mucosal inflammation 29%
NCT00796549 · Phase 2 · registry result, not featured evidence
50 mg
diarrhoea 87.8%
rash 68.3%
decreased appetite 53.7%
NCT00730925 · Phase 2 · registry result, not featured evidence
40 mg
rash 76.2%
diarrhoea 61.9%
decreased appetite 42.9%
NCT01003899 · Phase 2 · registry result, not featured evidence
anemia 83.3%
diarrhea 83.3%
anorexia 66.7%
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
nausea 100%
diarrhea 80%
anemia 60%
NCT02364609 · Phase 1 · registry result, not featured evidence · combination
Afa40+Ctx250
fatigue 75%
nausea 75%
chest pain 50%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Afa40+Ctx500
rash 84.1%
diarrhoea 73%
skin fissures 61.9%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
Afa40 Mono
diarrhoea 73%
fatigue 43.2%
rash 37.8%
NCT01090011 · Phase 1 · registry result, not featured evidence · monotherapy
Afa40+Ctx500
rash 47.2%
skin fissures 44.4%
fatigue 38.9%
NCT01090011 · Phase 1 · registry result, not featured evidence · combination
head/headache 87.5%
dysphagia 83.3%
infection gr0-2 neut, oral cavity 54.2%
NCT01074177 · Phase na · registry result, not featured evidence
i
diarrhoea 87.7%
paronychia 61.7%
dermatitis acneiform 49.3%
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 16 more results
diarrhoea 73.9%
rash 50%
decreased appetite 31.7%
NCT01360554 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
diarrhea 79.7% (placebo 19.7%)
rash acneiform 59.3% (placebo 10%)
dyspnea 57.9% (placebo 55.2%)
NCT01000025 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
diarrhoea 51.5%
rash 42.6%
weight decreased 34.7%
NCT04511533 · Phase 4 · registry result, not featured evidence
contusion 28.6%
diarrhoea 28.6%
dry skin 28.6%
NCT02382796 · Phase 2 · registry result, not featured evidence
45/60 mg
diarrhoea 87.5%
rash 50%
dry skin 43.8%
NCT01858389 · Phase 2 · registry result, not featured evidence
45/60 mg
diarrhoea 72.7%
rash 54.5%
nausea 40.9%
NCT01858389 · Phase 2 · registry result, not featured evidence
45 mg
diarrhoea 81.8%
nausea 42.4%
rash 42.4%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg + 100 mg
diarrhoea 78.8%
nausea 47%
rash 43.9%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 100%
rash 71.4%
chills 57.1%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 80.6%
decreased appetite 37.3%
rash 37.3%
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
45 mg
diarrhoea 92%
dermatitis acneiform 72%
pruritus 68%
NCT01465802 · Phase 2 · registry result, not featured evidence
diarrhoea 95.5%
dermatitis acneiform 76.4%
dry skin 43.8%
NCT00818441 · Phase 2 · registry result, not featured evidence
diarrhoea 93.3%
dermatitis acneiform 73.3%
fatigue 56.7%
NCT00818441 · Phase 2 · registry result, not featured evidence
diarrhoea 72%
dermatitis acneiform 64.5%
decreased appetite 29%
NCT00769067 · Phase 2 · registry result, not featured evidence
diarrhoea 88%
dermatitis acneiform 66%
fatigue 62%
NCT00548093 · Phase 2 · registry result, not featured evidence
diarrhoea 81.3%
dermatitis acneiform 75%
dry skin 43.8%
NCT00548093 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThe assessment timepoint is not available for both results.
  5. eTrial phases differ: Phase 4 versus Phase 2.
  6. fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  7. gTrial phases differ: Phase 2 versus Phase na.
  8. hPopulation comparability has not been reviewed for 30 of these studies.
  9. iPopulation comparability has not been reviewed for 14 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Afatinib

ORR 56.5% (n=230) vs 22.6% (n=115) Pemetrexed/Cisplatin40 mg
absolute value · percentage points
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
7.4% (n=390) vs 0.5% (n=195) placebo50 mg/Day
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Disease Control 90.4% (n=230) vs 80.9% (n=115) Pemetrexed/Cisplatin40 mg
absolute value · percentage points
NCT00949650 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Overall Survival 10.87 vs 11.73 placebo months @ 52wk50 mg/Day
time to event · months
Final analysis (526 deaths)
NCT00656136 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3
Clinical Benefit 82.2% (n=129)
responder rate · % of participants
No placebo or comparator arm
NCT00525148 · Phase 2
Duration of Clinical Benefit 18.83 months
time to event · months
No placebo or comparator arm
NCT00525148 · Phase 2 · converted to months from 81.6 weeks as posted
Time to Response 38.8% (n=129) @ 4wk
responder rate · % of participants
No placebo or comparator arm
NCT00525148 · Phase 2
show 6 more results
12.4% (n=129) @ 8wk
NCT00525148 · Phase 2
1.6% (n=129) @ 12wk
NCT00525148 · Phase 2
5.4% (n=129) @ 20wk
NCT00525148 · Phase 2
0% (n=129) @ 28wk
NCT00525148 · Phase 2
1.6% (n=129) @ 36wk
NCT00525148 · Phase 2
0% (n=129) @ 44wk
NCT00525148 · Phase 2
Disease Control 92.6% (n=242) vs 76.2% (n=122) Gemcitabine / Cisplatin40mg
responder rate · % of participants
NCT01121393 · Phase 3
Time to Response 49.2% (n=242) vs 13.1% (n=122) Gemcitabine / Cisplatin @ 6wk40mg
responder rate · % of participants
NCT01121393 · Phase 3
show 13 more results
59.9% (n=242) vs 19.7% (n=122) Gemcitabine / Cisplatin @ 12wk40mg
NCT01121393 · Phase 3
64% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 18wk40mg
NCT01121393 · Phase 3
64.9% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 24wk40mg
NCT01121393 · Phase 3
65.7% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 30wk40mg
NCT01121393 · Phase 3
66.1% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 36wk40mg
NCT01121393 · Phase 3
66.5% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 42wk40mg
NCT01121393 · Phase 3
66.5% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 48wk40mg
NCT01121393 · Phase 3
66.9% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 60wk40mg
NCT01121393 · Phase 3
66.9% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 72wk40mg
NCT01121393 · Phase 3
66.9% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 84wk40mg
NCT01121393 · Phase 3
67.4% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 96wk40mg
NCT01121393 · Phase 3
67.4% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 108wk40mg
NCT01121393 · Phase 3
67.8% (n=242) vs 23% (n=122) Gemcitabine / Cisplatin @ 120wk40mg
NCT01121393 · Phase 3
Duration of Disease Control 11.07 vs 5.65 Gemcitabine / Cisplatin months40mg
time to event · months
NCT01121393 · Phase 3
Weight -0.76 vs 0 Gemcitabine / Cisplatin kg40mg
absolute change · kg
Change from baseline at last value
NCT01121393 · Phase 3
Time to Deterioration Pain 6.93 vs 3.38 Gemcitabine / Cisplatin months40mg
time to event · months
NCT01121393 · Phase 3
ORR 5.5% (n=398) vs 2.8% (n=397) Erlotinib
event count · % of participants
NCT01523587 · Phase 3 · converted to % from 22 Participants as posted

+ 27 further endpoints in the CSV export.

Dacomitinib PF-00299804

Overall Survival 56.4 vs 45.7 Gefitinib probability of survival @ 130wk
absolute value · probability of survival
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Stable Disease 13.2% (n=227) vs 12% (n=225) Gefitinib
event count · % of participants
Stable disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 30 Participants as posted
show 1 more result
16.7% (n=227) vs 21.8% (n=225) Gefitinib*
Stable disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 38 Participants as posted
Progressive Disease 5.3% (n=227) vs 6.7% (n=225) Gefitinib
event count · % of participants
Progressive disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 12 Participants as posted
show 1 more result
4% (n=227) vs 4.9% (n=225) Gefitinib*
Progressive disease
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 · converted to % from 9 Participants as posted
Duration of Response 14.8 vs 8.3 Gefitinib months
time to event · months
DoR: IRC review
NCT01774721 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Complete 0% (n=16)45/60 mg
responder rate · % of participants
No placebo or comparator arm
Complete response (CR)
NCT01858389 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Partial 6.3% (n=16)45/60 mg
responder rate · % of participants
No placebo or comparator arm
Partial response (PR)
NCT01858389 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
Stable Disease 43.8% (n=16)45/60 mg
event count · % of participants
No placebo or comparator arm
Stable disease/no response
NCT01858389 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
PFS 37.5% (n=16) @ 16wk45/60 mg
responder rate · % of participants
No placebo or comparator arm
NCT01858389 · Phase 2 · registry result, not featured evidence
show 2 more results
25.3% (n=25) @ 16wk45/60 mg
NCT01858389 · Phase 2 · registry result, not featured evidence
76.9% (n=89) @ 16wk
NCT00818441 · Phase 2 · registry result, not featured evidence
Skindex-16 3.2 score @ 1wk45 mg
absolute change · score
No placebo or comparator arm
Total: Cycle 1 Day 8 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-1.7 score @ 1wk45 mg + 100 mg
Total: Cycle 1 Day 8 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
5.3 score @ 1wk45 mg
Total: Cycle 1 Day 8 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
Skindex-16 17.9 score @ 2wk45 mg
absolute change · score
No placebo or comparator arm
Total: Cycle 1 Day 15 (n=41, 42, 3)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
2.7 score @ 2wk45 mg + 100 mg
Total: Cycle 1 Day 15 (n=41, 42, 3)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
28.4 score @ 2wk45 mg
Total: Cycle 1 Day 15 (n=41, 42, 3)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
Skindex-16 15.9 score @ 3wk45 mg
absolute change · score
No placebo or comparator arm
Total: Cycle 1 Day 22 (n=42, 40, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
4 score @ 3wk45 mg + 100 mg
Total: Cycle 1 Day 22 (n=42, 40, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
35 score @ 3wk45 mg
Total: Cycle 1 Day 22 (n=42, 40, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
Skindex-16 13.1 score @ 4wk45 mg
absolute change · score
No placebo or comparator arm
Total: Cycle 2 Day 1 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
5.1 score @ 4wk45 mg + 100 mg
Total: Cycle 2 Day 1 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination
20.2 score @ 4wk45 mg
Total: Cycle 2 Day 1 (n=41, 42, 4)
NCT01465802 · Phase 2 · registry result, not featured evidence · combination

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afatinib's landscape · Dacomitinib PF-00299804's landscape